Carlos Arturo Castañeda Altamirano

Farmacia y Bioquímica
Auxiliar, Departamento Académico de Farmacología, Bromatología Y Toxicología
Titular, Biotecnología microbiana y salud
Colaborador, Alimentos y salud

Emailcarlos.castaneda@unmsm.edu.pe

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Carlos Arturo Castañeda Altamirano is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

1087 Citations
17 h-Index
32 Article
6 Review article
1 Scientific review

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
International Immuno-Oncology Biomarker Working Group, 1 Dec 2020, In: npj Breast Cancer. 6, 1, 15.
Research output: Contribution to journal › Review article › peer-review

Open Access
3 Scopus citations
Covid-19 en pacientes con cáncer: Revisión sistemática
Castañeda, C. A., Castillo, M., Rojas-Vilca, J. L., Fuentes, H. & Gómez, H. L., 1 Oct 2020, In: Revista Peruana de Medicina de Experimental y Salud Publica. 37, 4, p. 611-619 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Human epidermal growth factor receptor 2–positive breast cancer is associated with Indigenous American ancestry in Latin American women
COLUMBUS Consortium, May 2020, In: Cancer Research. 80, 9, p. 1893-1901 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
4 Scopus citations
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
the International Immuno-Oncology Biomarker Working Group, 1 Dec 2020, In: npj Breast Cancer. 6, 1, 17.
Research output: Contribution to journal › Article › peer-review

Open Access
13 Scopus citations
Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial
Delaloge, S., Piccart, M., Rutgers, E., Litière, S., van’t Veer, L. J., van den Berkmortel, F., Brain, E., Dudek-Peric, A., Gil-Gil, M., Gomez, P., Hilbers, F. S., Khalil, Z., Knox, S., Kuemmel, S., Kunz, G., Lesur, A., Pierga, J. Y., Ravdin, P., Rubio, I. T., Saghatchian, M. & 80 others, Smilde, T. J., Thompson, A. M., Viale, G., Zoppoli, G., Vuylsteke, P., Tryfonidis, K., Poncet, C., Bogaerts, J., Cardoso, F., Benn, K., Ciruelos, E., Corochan, S., Cuny, J., de la Pena, L., DeLorenzi, M., Eekhout, I., Gluz, O., Golfinopoulos, V., Goulioti, T., Harbeck, N., Hilal, V., Lemonnier, J., Ławniczak, M., Marini, L., Matos, E., Morales, P., Murray, K., Nitz, U., Passalaqua, R., Remmelzwaal, J., Slaets, L., Sotiriou, C., Straehle, C., Straley, M., Theron, N., Todeschini, R., Urunkar, M., Aalders, K., Bines, J., Bedard, P., Bozovic, I., Braga, S., Castaneda, C., Celebic, A., Colichi, C., Criscitiello, C., Dal Lago, L., Demonty, G., Drukker, C., Fei, F., Lia, M., Loi, S., Mook, S., Moulin, C., Sreseli, R., Werutsky, G., Corachan, S., Dudek-Peric, A., Wheeler, L., Dif, N., Rizzetto, G., Beauvois, M., Meirsman, L., Breyssens, H., Decker, N., Engelen, K., Akropovic, A., Harrison, J., Henot, F., Celis, M., de Jongh, B., Delmotte, I., Daubie, V., Goossens, R., Helsen, N., Hourt, L., Janssen, S., Soete, V., Vansevenant, K. & Hermans, C., 10 Apr 2020, In: Journal of Clinical Oncology. p. 1186-1197 12 p.
Research output: Contribution to journal › Article › peer-review
2 Scopus citations

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Covid-19 en pacientes con cáncer: Revisión sistemática

Human epidermal growth factor receptor 2–positive breast cancer is associated with Indigenous American ancestry in Latin American women

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial